Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations

NCT02302742 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT02302742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02302742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations
Lead sponsor
University of Kansas Medical Center
Phase
Observational
Overall status
Recruiting
Start date
March 22, 2011
Completion date
December 31, 2026
Enrollment
3,000 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hereditary breast and ovarian cancer